Holoxan® [ifosfamide]

Holoxane - affects inoperable malignant tumors sensitive to ifosfamide from the composition, such as lung cancer, ovarian cancer, breast cancer, testicular tumor, soft tissue sarcoma, pancreatic cancer, kidney cancer, cervical cancer, head and neck tumors, malignant lymphomas.

Less toxic compared to Endoxan and therefore it is more preferable in pediatric oncology.

Contraindications

Holoxan should not be used with a known hypersensitivity to ifosfamide, a sharp decrease in bone marrow hematopoiesis, a decrease in kidney function, and obstruction of the outflow of urine during pregnancy.

Mode of application

The total dose of the drug per course is 250-300 mg / kg (10-12 g / m2).

As a rule, the drug is administered intravenously over 5 days at 50-60 mg / kg (2.0-2.4 g / m2).

It can also be administered as a long (24 hours) intravenous infusion at a dose of 5-8 g / m2.

It is recommended to be administered in the morning.

The course of treatment can be repeated no earlier than 3-4 weeks.

Other doses and modes of administration are also possible on the recommendation of a doctor.

Adverse reactions

Depending on the dose, the following side effects may occur: nausea, vomiting, hair loss, bone marrow damage with a decrease in the number of leukocytes and platelets, a decrease in immunity, cystitis, impaired function of the sex glands, and sometimes impaired renal function.

In rare cases, there may be impaired liver function.

Reversible encephalopathies of various degrees may occur, expressed in disorientation, confusion.

With the introduction of hypersensitivity reactions may develop, may enhance the skins response to radiation.

Storage conditions

Store at a temperature not exceeding + 25 ° C.

It should not be applied after the date indicated on the package.

Keep out of reach of children.